^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iadademstat (ORY-1001)

    i
    Company:
    Oryzon
    Drug class:
    LSD1 inhibitor
    Related drugs:
    Apply
    Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (NCT06514261)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/16/2025
    Initiation :
    12/18/2024
    Primary completion :
    09/16/2026
    Completion :
    09/16/2026
    TP53 • BCL2 • NF1 • MCL1 • BCL2L1 • BAX
    |
    Venclexta (venetoclax) • azacitidine • iadademstat (ORY-1001)
    Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) (NCT05546580)
    Phase 1
    Oryzon Genomics S.A.
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    11/14/2022
    Primary completion :
    01/31/2025
    Completion :
    07/30/2025
    FLT3
    |
    FLT3 mutation • FLT3 D835 • FLT3 I836
    |
    Xospata (gilteritinib) • iadademstat (ORY-1001)